How to order
Contact us
Thanks for visiting the Mulpleo website, if you have any questions about the information on this page or Mulpleo in general you can visit our FAQs page or contact us for more information.
Sign up
Thanks for visiting the Mulpleo website. If you would like to receive information and updates from us, you can sign up here.
DON'T LET SEVERE
THROMBOCYTOPENIA
STAND IN THE WAY
OF YOUR PROCEDURES
Mulpleo was the first thrombopoietin (TPO) receptor agonist approved for the treatment of severe thrombocytopenia (TCP) in adult patients with chronic liver disease (CLD) undergoing invasive procedures.1
Discover the latest information about upcoming events, articles, videos and case studies from the field’s leading experts.
Positive recommendations from NICE and SMC2,3
Once-daily for 7 days1
TPO receptor agonist1
With or without food1
Procedure performed from day 9 after the start of Mulpleo treatment1*
Oral tablet1
Mulpleo provides an extended median procedural window of approximately 3 weeks4
*Platelet count should be measured prior to a procedure.1 Mulpleo has no known drug-drug interactions.
Please see the Mulpleo SmPC for further information.1,5
Severe TCP in CLD patients can result in complications in patient care, often leading to delayed or cancelled procedures6,7
Estimates suggest that the mean overall healthcare costs in patients with CLD are 3.5x higher in patients with thrombocytopenia vs. non-thrombocytopenic patients (p<0.01).8 Compared with CLD patients with a platelet count of >100x109/L, patients with CLD and a platelet count of ≤100x109/L experience:7
more liver disease-related ambulatory visits (p<0.01)7
greater likelihood of liver disease-related emergency hospital visits (p<0.01)7
more likely to have liver disease-related inpatient hospital stays (p<0.01)7
– National Institute for Health and Care Excellence (NICE), 20202
This is only for patients already prescribed Mulpleo.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to Shionogi on Tel: +44 (0)20 3053 4190 or via contact@shionogi.eu.
References
Mulpleo (lusutrombopag) Summary of Product Characteristics.
National Institute for Health and Care Excellence (NICE). Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure. TA617. January 2020. Available at: https://www.nice.org.uk/guidance/ta617. (Accessed January 2022).
Scottish Medicines Consortium (SMC). Lusutrombopag (Mulpleo). December 2019. Available at: https://www.scottishmedicines.org.uk/medicinesadvice/lusutrombopag-mulpleo-full-smc2227/. (Accessed January 2022).
Brown RS, Imawar M, Izumi N, et al. JHEP Rep. 2021;3(2):100228
Katsube T, Inoue Y, Fukuhara T, et al. Eur J Clin Pharmacol. 2020;76:1659–1665.
Afdhal N, McHutchison J, Brown R, et al. J Hepatol. 2008;48(6):1000–1007.
Poordad F, Theodore D, Sullivan J, et al. J Med Econ. 2012;15(1):112–124.
Brown Jr RS. Alimentary Pharmacol Ther. 2007;26(1):41–48.
PP-UK-LUS-0316. Date of preparation: December 2023